Celsion Corp (CLSN)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Celsion Corp (CLSN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013919
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:84
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Celsion Corp (Celsion) is an oncology company that focuses on developing a portfolio of new cancer treatments, including directed chemotherapies, RNA based therapies and DNA-mediated immunotherapy. The company’s three platform technologies including Lysolipid Thermally Sensitive Liposomes (LTSL), TheraPlas and TheraSilence provide the foundation for a wide range of therapeutics for common and difficult-to-treat forms of cancers. Its lead product candidate ThermoDox is a proprietary dosage form of doxorubicin based LTSL technology in a Phase III clinical trial for the treatment of non-resectable hepatocellular carcinoma (HCC) and a Phase II clinical trial for recurrent chest wall (RCW) breast cancer. It is also developing a comprehensive pipeline of targeted therapeutic agents. Celsion is headquartered in Lawrenceville, New Jersey, the US.

Celsion Corp (CLSN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Celsion Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Celsion Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Celsion Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Celsion Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Celsion Corp, Medical Devices Deals, 2011 to YTD 2017 10
Celsion Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Celsion Corp, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Celsion Enters into Partnership with Children’s Research Institute 13
Celsion Enters into Agreement with Zhejiang Hisun Pharma 14
Celsion Expands Technology Development Agreement With Zhejiang Hisun Pharma 15
Celsion Enters Into Technology Development Agreement With Zhejiang Hisun Pharma For ThermoDox 16
Licensing Agreements 18
Celsion Enters Into Licensing Agreement With Duke University 18
Equity Offering 19
Celsion Plans to Raise up to USD7.4 Million in Private Placement of Shares up on Exercise of Warrants 19
Celsion Prices Public Offering of Shares for USD6.6 Million 20
Celsion Plans to Raise Funds through Private Placement of Shares up on Exercise of Warrants 21
Celsion Raises USD4.2 Million in Private Placement of Shares and Warrants 22
Celsion to Raise up to USD2.4 Million in Public Offering of Shares 24
Celsion Raises Funds through Private Placement of Shares upon Exercise of Warrants 25
Celsion Raises USD0.6 Million in Private Placement of Shares upon Exercise of Warrants 26
Celsion Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 27
Celsion Raises USD5 Million in Public Offering of Shares and Warrants 28
Celsion Raises USD1.8 Million in Private Placement of Shares and Warrants 29
Celsion Plans to Raise USD12.3 Million in Private Placement of Shares upon Exercise of Warrants 30
Celsion Raises Funds through Private Placement of Shares up on Exercise of Warrants 31
Celsion Raises USD6 Million in Private Placement of Shares 32
Celsion Raises USD8 Million in Private Placement of Shares 33
Celsion Announces Private Placement Of Common Stock For US$15 Million 34
Celsion Raises USD9.8 Million in Private Placement of Shares 35
Celsion Completes Private Placement Of Shares For US$15 Million 36
Celsion Completes Public Offering Of Common Stock For US$7 Million 37
Celsion Completes Registered Direct Offering Of Common Stock For US$15 Million 38
Celsion Completes Registered Direct Offering Of Units For US$13 Million 39
Celsion Completes Registered Direct Offering Of Units For US$5.6 Million 40
Celsion Completes Registered Direct Offering Of US$6.6 Million 41
Celsion Completes Private Placement Of US$8.53 Million 43
Celsion Completes Registered Direct Offering Of Units For US$5.1 Million 44
Acquisition 46
Celsion Completes Acquisition of Egen Biopharma Company 46
Celsion Explores Acquisition Opportunities 48
Celsion Corp – Key Competitors 49
Celsion Corp – Key Employees 50
Celsion Corp – Locations And Subsidiaries 51
Head Office 51
Recent Developments 52
Financial Announcements 52
Nov 14, 2017: Celsion Reports Third Quarter 2017 Financial Results and Provides Business Update 52
Aug 15, 2017: Celsion Reports Second Quarter 2017 Financial Results and Provides Business Update 55
May 12, 2017: Celsion Reports First Quarter 2017 Financial Results and Provides Business Update 58
Mar 16, 2017: Celsion Reports Year End 2016 Financial Results and Provides Business Update 60
Nov 10, 2016: Celsion Reports Third Quarter 2016 Financial Results 62
Aug 15, 2016: Celsion Reports Second Quarter 2016 Financial Results and Provides Business Update 64
May 16, 2016: Celsion Reports First Quarter 2016 Financial Results and Provides Business Update 66
Mar 30, 2016: Celsion Reports Year End 2015 Financial Results and Provides Business Update 68
Corporate Communications 70
Aug 04, 2017: Celsion to Delist from the Tel Aviv Stock Exchange 70
Product News 71
04/12/2016: Celsion Announces Upcoming Presentation at AACR 2016 Highlighting Potential of GEN-1 IL-12 Immunotherapy in Ovarian Cancer 71
Clinical Trials 72
May 24, 2016: Celsion Announces Presentation of OVATION Study Clinical Trial Design at Upcoming ASCO 2016 Meeting 72
May 02, 2016: Celsion Announces Positive Data from the First Cohort of Patients in the OVATION Study 74
Apr 26, 2016: Celsion Announces Enrollment of First Patient in the OPTIMA Study in China 76
Apr 19, 2016: Celsion Presents Compelling Data at AACR 2016 Demonstrating Synergistic Anti-Cancer Effect of GEN-1 IL-12 Immunotherapy Plus Avastin and Doxil 77
Mar 16, 2016: Celsion Announces Presentation of Preclinical Data for GEN-1 IL-12 Immunotherapy in Combination with Avastin and Doxil at the AACR Annual Meeting 2016 78
Mar 07, 2016: Celsion Announces Launch of the OPTIMA Study in China 80
Feb 12, 2016: Celsion Highlights Recent Pipeline Developments for its GEN-1 Immunotherapy Program and Provides Business Update 81
Jan 07, 2016: Celsion Reports Translational Research Data from its Phase 1b Study of GEN-1 Immunotherapy in Recurrent Ovarian Cancer 83
Appendix 84
Methodology 84
About GlobalData 84
Contact Us 84
Disclaimer 84

List of Tables
Celsion Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Celsion Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Celsion Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Celsion Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Celsion Corp, Deals By Therapy Area, 2011 to YTD 2017 9
Celsion Corp, Medical Devices Deals, 2011 to YTD 2017 10
Celsion Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Celsion Enters into Partnership with Children's Research Institute 13
Celsion Enters into Agreement with Zhejiang Hisun Pharma 14
Celsion Expands Technology Development Agreement With Zhejiang Hisun Pharma 15
Celsion Enters Into Technology Development Agreement With Zhejiang Hisun Pharma For ThermoDox 16
Celsion Enters Into Licensing Agreement With Duke University 18
Celsion Plans to Raise up to USD7.4 Million in Private Placement of Shares up on Exercise of Warrants 19
Celsion Prices Public Offering of Shares for USD6.6 Million 20
Celsion Plans to Raise Funds through Private Placement of Shares up on Exercise of Warrants 21
Celsion Raises USD4.2 Million in Private Placement of Shares and Warrants 22
Celsion to Raise up to USD2.4 Million in Public Offering of Shares 24
Celsion Raises Funds through Private Placement of Shares upon Exercise of Warrants 25
Celsion Raises USD0.6 Million in Private Placement of Shares upon Exercise of Warrants 26
Celsion Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 27
Celsion Raises USD5 Million in Public Offering of Shares and Warrants 28
Celsion Raises USD1.8 Million in Private Placement of Shares and Warrants 29
Celsion Plans to Raise USD12.3 Million in Private Placement of Shares upon Exercise of Warrants 30
Celsion Raises Funds through Private Placement of Shares up on Exercise of Warrants 31
Celsion Raises USD6 Million in Private Placement of Shares 32
Celsion Raises USD8 Million in Private Placement of Shares 33
Celsion Announces Private Placement Of Common Stock For US$15 Million 34
Celsion Raises USD9.8 Million in Private Placement of Shares 35
Celsion Completes Private Placement Of Shares For US$15 Million 36
Celsion Completes Public Offering Of Common Stock For US$7 Million 37
Celsion Completes Registered Direct Offering Of Common Stock For US$15 Million 38
Celsion Completes Registered Direct Offering Of Units For US$13 Million 39
Celsion Completes Registered Direct Offering Of Units For US$5.6 Million 40
Celsion Completes Registered Direct Offering Of US$6.6 Million 41
Celsion Completes Private Placement Of US$8.53 Million 43
Celsion Completes Registered Direct Offering Of Units For US$5.1 Million 44
Celsion Completes Acquisition of Egen Biopharma Company 46
Celsion Explores Acquisition Opportunities 48
Celsion Corp, Key Competitors 49
Celsion Corp, Key Employees 50

★海外企業調査レポート[Celsion Corp (CLSN)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • AIA Group Limited:企業の戦略・SWOT・財務情報
    AIA Group Limited - Strategy, SWOT and Corporate Finance Report Summary AIA Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Showa Shell Sekiyu K.K.:企業の戦略・SWOT・財務情報
    Showa Shell Sekiyu K.K. - Strategy, SWOT and Corporate Finance Report Summary Showa Shell Sekiyu K.K. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Lipocine Inc (LPCN):企業の財務・戦略的SWOT分析
    Summary Lipocine Inc (Lipocine) is a pharmaceutical company that develops and commercializes treatment for men's and women's health. The company’s pipeline products for men’s health include LPCN 1111 and LPCN 1021; and for women’s health include LPCN 1107. Its LPCN 1111 is an oral testosterone produ …
  • Gridsum Holding, Inc. (GSUM):企業の財務・戦略的SWOT分析
    Gridsum Holding, Inc. (GSUM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Banco Davivienda Sa:企業の戦略・SWOT・財務分析
    Banco Davivienda Sa - Strategy, SWOT and Corporate Finance Report Summary Banco Davivienda Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • PT Astra International Tbk:企業の戦略・SWOT・財務情報
    PT Astra International Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Astra International Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • CGI Group Inc (GIB.A):企業の財務・戦略的SWOT分析
    CGI Group Inc (GIB.A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Covestro AG (1COV):企業の財務・戦略的SWOT分析
    Covestro AG (1COV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Vectura Group Plc (VEC):医療機器:M&Aディール及び事業提携情報
    Summary Vectura Group Plc (Vectura) is a formulation and device business for inhaled airways products providing an integrated inhaled drug delivery platform. It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD) …
  • Alucon Public Company Limited:戦略・SWOT・企業財務分析
    Alucon Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary Alucon Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Bon Secours Health System Inc:企業の戦略的SWOT分析
    Bon Secours Health System Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Detroit Medical Center:企業の戦略的SWOT分析
    Detroit Medical Center - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Perdue Farms Inc.:企業の戦略・SWOT・財務分析
    Perdue Farms Inc. - Strategy, SWOT and Corporate Finance Report Summary Perdue Farms Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Skechers USA Inc (SKX):企業の財務・戦略的SWOT分析
    Skechers USA Inc (SKX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Southern Co (SO):企業の財務・戦略的SWOT分析
    Southern Co (SO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • LG Electronics, Inc.:戦略・SWOT・企業財務分析
    LG Electronics, Inc. - Strategy, SWOT and Corporate Finance Report Summary LG Electronics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • RainDance Technologies Inc-医療機器分野:企業M&A・提携分析
    Summary RainDance Technologies Inc (RDT) is a developer of genomic tools for non-invasive liquid biopsy applications. The company’s products include RainDrop Plus, a digital PCR system that provides picoliter droplets for multiplex detection of HIV and DNA. It also offers RainDrop Plus digital PCR s …
  • Allergan plc:企業のM&A・事業提携・投資動向
    Allergan plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Allergan plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Sodexo, Inc.:企業の戦略的SWOT分析
    Sodexo, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Plasticell Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Plasticell Ltd (Plasticell) is a biotechnology company that develops therapies derived from research using its combinatorial cell culture technology. The company offers therapeutic programs such as expansion of hematopoietic stem cells from bone marrow and cord blood, platelets and immune ce …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆